A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer
Latest Information Update: 16 Dec 2025
At a glance
- Drugs Camrelizumab (Primary) ; Famitinib (Primary)
- Indications Cervical cancer
- Focus Adverse reactions
Most Recent Events
- 11 Dec 2025 New trial record